EUVIMEDEUVIMED entdecken
Crossref

5-aza-2-deoxycytidine improves skeletal muscle function in a mouse model for recessive RYR1 -related congenital myopathy

Alexis Ruiz, Faiza Noreen, Hervé Meier, Katarzyna Buczak, Francesco Zorzato, Susan Treves iD

Human Molecular Genetics · 2025

DOI: 10.1093/hmg/ddaf021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Molecular Genetics, 2025. Verfasst von Alexis Ruiz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Neuromuscular Research Group, Departments of Neurology and Biomedicine, Basel University Hospital, Hebelstrasse 20, 4031 Basel, Switzerland. Hauptthemen laut MEDLINE: Muscle, Skeletal, Ryanodine Receptor Calcium Release Channel, Decitabine, Myotonia Congenita. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RYR1-related congenital myopathies are rare disorders that severely impair muscle function and the quality of life of patients and their families. To date no pharmacological therapies are available to treat the severe muscle weakness of affected patients. The most severe forms of RYR1-related congenital myopathies are caused by compound heterozygous mutations (nonsense/frameshift in one allele and a missense mutation in the other), leading to reduced RyR1 protein levels and altered biochemical composition of muscles. In this pre-clinical study, we treated a mouse model carrying the RyR1 p.Q1970fsX16 + p.A4329D compound heterozygous pathogenic variants (dHT mice) for 15 weeks with 0.05 mg/kg 5-aza-2′-deoxycytidine, an FDA-approved drug targeting DNA methyltransferases. We evaluated muscle strength, calcium homeostasis and muscle proteome and report that drug treatment improves all investigated parameters in dHT mice. Importantly, the beneficial effects were particularly significant in fast twitch muscles which are the first muscles to be impaired in patients. In conclusion, this study provides proof of concept for the pharmacological treatment of patients with recessive RYR1-related congenital myopathies with the FDA approved 5-aza-2′-deoxycytidine, supporting its use in a phase 1/2 clinical trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscle, SkeletalRyanodine Receptor Calcium Release ChannelDecitabineMyotonia CongenitaMuscular DiseasesAnimalsMiceDisease Models, AnimalHumansMuscle StrengthCalciumMutationMale

Stichwörter der Autor:innen

5-AzaCongenital myopathiesEpigenetic changesImproved muscle functionRYR1

Substanzen

Ryanodine Receptor Calcium Release ChannelDecitabineryanodine receptor 1, mouseCalcium

Autor:innen und Institutionen

  • Neuromuscular Research Group, Departments of Neurology and Biomedicine, Basel University Hospital, Hebelstrasse 20, 4031 Basel, Switzerland.
  • Genome plasticity group, Department of Biomedicine, University of Basel, Mattenstrasse 28 4058, Basel, Switzerland.
  • Proteomics Core Facility, Biozentrum, University of Basel, Spitalstrasse 41 4056 Basel, Switzerland.
  • Department of Life Science and Biotechnology, University of Ferrara, Via Borsari 46, 44121 Ferrara, Italy.

ORCID-Profile: Susan Treves

Zitieren

APA

Ruiz, A., Noreen, F., Meier, H., Buczak, K., Zorzato, F., & Treves, S. (2025). 5-aza-2-deoxycytidine improves skeletal muscle function in a mouse model for recessive RYR1 -related congenital myopathy. Human Molecular Genetics. https://doi.org/10.1093/hmg/ddaf021

Vancouver

Ruiz A, Noreen F, Meier H, Buczak K, Zorzato F, Treves S. 5-aza-2-deoxycytidine improves skeletal muscle function in a mouse model for recessive RYR1 -related congenital myopathy. Human Molecular Genetics. 2025. doi:10.1093/hmg/ddaf021

BibTeX
@article{Ruiz2025,
  author = {Ruiz, Alexis and Noreen, Faiza and Meier, Hervé and Buczak, Katarzyna and Zorzato, Francesco and Treves, Susan},
  title = {5-aza-2-deoxycytidine improves skeletal muscle function in a mouse model for recessive RYR1 -related congenital myopathy},
  journal = {Human Molecular Genetics},
  year = {2025},
  doi = {10.1093/hmg/ddaf021}
}
Kostenlos starten →